Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy

Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy. The project called CGT2 is headed by Scandinavian’s leading gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”), and aims to develop an AAV-based gene therapy for the treatment of the rare disease partial lipodystrophy.

The CGT2 project consortium includes a research group of the University of Hamburg (“Universitätsklinikum Hamburg Eppendorf”) with its expertise in lipid research.

EU’s Eurostars program is the largest international financing program for SMEs wishing to cooperate on research and development. Competition is high and funding is only allocated to projects that come high in the rankings. Eurostars has now allocated a total of EUR 882,500 in development funding to the CGT2 project.

Accelero will be responsible for the development of human monoclonal antibodies targeting CGT2. One integral part is the setup and development of appropriate immunoassays as tools for in vitro as well as in vivo CGT2 proof-of-concept characterization.

Contact:

Accelerō® Bioanalytics GmbH
Volmerstrasse 9A, D-12489 Berlin
Phone: +49 30 610910-300 (Office)
Phone: +49 30 610910-307 (GLP Safety Level S2 Laboratories)
Email: service(at)accelero-bioanalytics.com
www.accelero-bioanalytics.com

Press release Accelero, 22 February 2021